GSK shares fall on news that vaccines boss will retire

15 June 2016

Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017.

Shares opened at $40.23 on the NYSE, before falling to a low of $39.80. The stock closed at $40.05.

Slauoi, also a former head of research and development, is to give up his seat on the board even sooner, leaving this post in March 2017, while continuing to serve as an advisor to the company and its board in the intervening three months until his retirement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK